Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DRIO vs MYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MYO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

MYO Overall Winner 6-Pillar Tally: DRIO 1 – 4 MYO (1 Tie) Matrix Metrics: DRIO 4 – 6 MYO

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DRIO carries a Unified Composite Score of 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin).

  • Composite vs. Pillar Nuance: While DRIO currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -142.7% operating margin) and revenue trajectory (+22.2% vs. +6.1% YoY).
  • Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DRIO vs MYO
DRIO NASDAQ
DarioHealth Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-8.33% 1D
Market Cap $16.3M
TTM Revenue $21M
Forward P/E 10.6x
Beta / 30D Vol 0.45β · 182% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.0%), weak momentum, RSI 24
RSI-14: 24.0 · SMA20: $2.34 · SMA50: $4.46
MYO NYSE American Head-to-Head Winner
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (DRIO 1 – 4 MYO)

Columns: Metric · DRIO · MYO
1. Valuation Multiples DRIO
Forward P/E 10.6x N/M
Trailing P/E 10.6x N/M
PEG Ratio N/M N/M
EV / Revenue 0.8x 0.9x
2. Growth & Scale MYO
Revenue Growth (YoY) +6.1% +22.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M $46M
Market Cap $16.3M $33.7M
3. Profitability & Quality MYO
Gross Margin 61.3% 70.1%
Operating Margin -142.7% -21.8%
Net Profit Margin -159.9% -33.1%
Return on Equity (ROE) -46.6% -173.5%
4. Balance Sheet & Cash Flow MYO
Cash Generation (TTM) -$28M EBITDA -$9.1M
Cash Flow Margin -132.8% EBITDA Mgn -20.0%
Net Cash / Leverage $6.37 Book/Sh · -46.6% ROE $8.9M Net Debt (3.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 266.0% (81st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DRIO (4) vs MYO (6)
Institutional Metric DRIO MYO Criterion Row Edge
Market Capitalization
Scale
$16.3M $33.7M Larger Scale MYO
Trailing P/E Ratio
Valuation
10.6x N/M Lower Multiple DRIO
Forward P/E Ratio
Valuation
10.6x N/M Lower Multiple DRIO
Revenue Growth (YoY)
Growth
+6.1% +22.2% Higher Growth MYO
Operating Margin (TTM)
Profitability
-142.7% -21.8% Higher Margin MYO
Net Profit Margin
Profitability
-159.9% -33.1% Higher Margin MYO
Return on Equity (ROE)
Capital Efficiency
-46.6% -173.5% Higher ROE DRIO
52-Week Range Position
Momentum
2% ($1–$15) 16% ($1–$2) Stronger Trend MYO
Beta / 30D Volatility
Risk Regime
0.45β · 182% Vol 2.22β · 107% Vol Lower Realized Risk MYO
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 40.1 / 100 (SELL) Higher Composite DRIO
Trailing 12M Revenue (USD)
Operating Scale
$21M $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.3% 70.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M EBITDA ($6.37 Book/Sh · -46.6% ROE) -$9.1M ($8.9M Net Debt (3.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYO +27.77 pp
DRIO: -61.29% · MYO: -33.52%
3M Horizon MYO +40.04 pp
DRIO: -81.69% · MYO: -41.65%
6M Horizon MYO +61.19 pp
DRIO: -83.21% · MYO: -22.02%
1Y Horizon MYO +102.87 pp
DRIO: -90.57% · MYO: +12.3%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRIO vs MYO. Trailing 12-month operating profitability (DRIO -142.7% vs MYO -21.8%) and valuation multiples (DRIO 10.6x vs MYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DRIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.3%
Op. Margin-142.7%
ROE / Fwd P/E-46.6% · 10.6x
MYO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin70.1%
Op. Margin-21.8%
ROE / Fwd P/E-173.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DRIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DRIO Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $16.3M market capitalization and -142.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DRIO vs MYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over DarioHealth Corp. (DRIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DRIO carries a Unified Composite Score of 42.2/100 (HOLD) at $1.32 (10.6x Forward P/E, -142.7% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin). Composite vs. Pillar Nuance: While DRIO currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -142.7% operating margin) and revenue trajectory (+22.2% vs. +6.1% YoY). Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYO leads the Growth & Scale pillar: DRIO posts +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin), compared with MYO at +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin). On trailing 12-month operating scale, DRIO generates $21M in USD-normalized revenue versus $46M for MYO. In operating R&D and SG&A reinvestment, DRIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MYO.

DRIO screens cheaper on headline valuation multiples. DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin), whereas MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRIO (-46.6% ROE) versus MYO (-173.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk). By comparison, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.